Wockhardt
Indian multinational pharmaceutical and biotechnology company
Last updated August 22, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Wockhardt is an Indian multinational pharmaceutical and biotechnology company headquartered in Mumbai. Its business spans branded generic medicines, biopharmaceuticals, vaccines, nutrition products, active pharmaceutical ingredients, and pharmaceutical manufacturing services. The company has operated manufacturing and subsidiary businesses in India, the United Kingdom, Ireland, France, the United States, and Germany, giving it a broader international footprint than a purely domestic Indian drug manufacturer. The business originated in the 1960s after Dr. Habil Khorakiwala’s father, Fakhruddin T. Khorakiwala, acquired Worli Chemical Works in 1959. The enterprise subsequently developed under the Wockhardt name, with Wockhardt Pvt. Ltd. incorporated in 1973 and Wockhardt Ltd. incorporated on 8 July 1999. During the 1990s, the company expanded its Indian pharmaceutical presence through products including the painkiller Proxyvon and medicines for cardiovascular conditions. It also moved beyond conventional formulations into biotechnology in 1995 and later into intravenous fluids. Wockhardt’s development strategy relied substantially on international acquisitions. Its disclosed transactions included Wallis Laboratory and Merind in 1998, CP Pharmaceuticals in the United Kingdom in 2003, Espharma in Germany in 2004, Dumex in India and Pinewood Laboratories in Ireland in 2006, and Morton Grove Pharmaceuticals in the United States and Negma in France in 2007. The acquisition program increased the company’s geographic reach and product capabilities, but also left it with a substantial debt burden. The reference material states that debt following these transactions approached Rs 38 billion and that Habil Khorakiwala subsequently left the managing-director position. In 2009, the board approved the appointments of Murtaza Khorakiwala as managing director and Huzaifa Khorakiwala as executive director. The company has also pursued biotechnology and vaccine-related capabilities. Wockhardt was described as the first company outside the United States and Europe to manufacture recombinant human insulin. During the COVID-19 pandemic, it entered into an agreement with the Government of the United Kingdom to fill and finish the Oxford–AstraZeneca vaccine at its Wrexham facility in Wales; the arrangement was later extended through August 2022. In August 2021, Wockhardt announced a contract-manufacturing agreement involving Dubai-based Enso Healthcare and Russia’s Human Vaccine LLC for Sputnik V and Sputnik Light vaccines in India. Wockhardt has faced significant regulatory scrutiny. In 2013, the United States Food and Drug Administration identified alleged widespread manufacturing and data-integrity problems at the company’s Aurangabad facility, including contamination concerns involving injectable medicines and violations of good manufacturing practice requirements. The FDA restricted exports from the facility. The episode became one of the most consequential quality and compliance events in the company’s history and affected perceptions of its regulated-market manufacturing operations. Alongside its commercial activities, Wockhardt is associated with the Wockhardt Foundation and Wockhardt Global Schools. The brand is therefore positioned as an internationally oriented pharmaceutical manufacturer combining Indian market operations with generic medicines, biotechnology, APIs, vaccines, and contract production. Its present status is active, although a complete account of current product portfolios, management, and manufacturing sites would require confirmation from current company filings and official corporate materials.
History
Wockhardt’s roots are associated with Worli Chemical Works, acquired in 1959 by Fakhruddin T. Khorakiwala. The enterprise developed under the leadership of his son, Dr. Habil Khorakiwala, and is generally dated to the 1960s. Wockhardt Pvt. Ltd. was incorporated in 1973, while Wockhardt Ltd. was incorporated on 8 July 1999. In the 1990s, Wockhardt strengthened its position in the Indian pharmaceutical market. Products cited in accounts of the company’s development include Proxyvon, a painkiller combining tramadol and paracetamol, and medicines for hypertension and other cardiovascular conditions, including lisinopril-based products. In 1995, Wockhardt entered biotechnology and subsequently expanded into intravenous fluids. The company also became involved in the development and manufacture of recombinant human insulin and was described as the first company outside the United States and Europe to manufacture that product category. Wockhardt pursued an aggressive internationalization and diversification program through acquisitions. It acquired Wallis Laboratory in the United Kingdom and Merind in India in 1998, CP Pharmaceuticals in the United Kingdom in 2003, Espharma in Germany in 2004, Dumex in India and Pinewood Laboratories in Ireland in 2006, and Morton Grove Pharmaceuticals in the United States and Negma in France in 2007. These transactions expanded its formulation businesses, geographic presence, and access to international markets. They also increased leverage: the reference account places debt following the acquisitions at close to Rs 38 billion. Habil Khorakiwala left the managing-director role, and on 31 March 2009 the board approved Murtaza Khorakiwala as managing director and Huzaifa Khorakiwala as executive director. The company’s portfolio has included formulations, biopharmaceuticals, APIs, vaccines, nutrition products, and manufacturing services. Wockhardt sold its nutrition business to Danone in 2011 for a reported $356 million, marking a significant portfolio reshaping and reducing its exposure to that segment. A major setback came in 2013, when the U.S. Food and Drug Administration reported serious problems at Wockhardt’s Aurangabad manufacturing facility. The findings included alleged widespread fraud and data-integrity failures, good-manufacturing-practice violations, and contamination involving injectable medicines. The FDA responded by restricting the facility’s ability to export medicines to the United States. The episode placed the company’s quality systems and regulated-market manufacturing under intense scrutiny. Reference material also states that Wockhardt officials repeatedly threatened FDA inspectors, adding a serious conduct dimension to the regulatory controversy. During the COVID-19 pandemic, Wockhardt became involved in vaccine production infrastructure in the United Kingdom. Its Wrexham, Wales facility was selected for fill-finish work on the Oxford–AstraZeneca vaccine under a contract with the British government. The arrangement was extended through August 2022. In August 2021, Wockhardt announced another vaccine manufacturing arrangement involving Dubai-based Enso Healthcare and Russia’s Human Vaccine LLC for Sputnik V and Sputnik Light production in India. The broader Wockhardt group has also been associated with philanthropic and education initiatives, including the Wockhardt Foundation and Wockhardt Global Schools. The company’s name has appeared in popular-culture discussions because a codeine- and promethazine-containing cough syrup associated with the brand is referenced in slang for recreational “lean”; this association is cultural rather than a statement about the company’s intended use of the medicine. Wockhardt remains an active Indian pharmaceutical company with international manufacturing, subsidiary, and commercial interests.
- 2021
Sputnik vaccine manufacturing agreement announced
[1]Wockhardt announced a contract-manufacturing agreement for Sputnik V and Sputnik Light vaccines in India.
- 2020
Oxford–AstraZeneca vaccine fill-finish agreement
[1]Wockhardt began fill-finish work for the Oxford–AstraZeneca COVID-19 vaccine at Wrexham in Wales under a UK government agreement.
- 2013
Aurangabad facility faces FDA restrictions
[1]The FDA restricted exports from the Aurangabad plant after identifying serious manufacturing and integrity concerns.
- 2011
Nutrition business sold to Danone
[1]Wockhardt sold its nutrition business to Danone for a reported $356 million.
- 2009
Khorakiwala family management transition
[1]The board approved Murtaza Khorakiwala as managing director and Huzaifa Khorakiwala as executive director on 31 March 2009.
- 2007
International acquisition program expanded
[1]The company acquired Morton Grove Pharmaceuticals in the United States and Negma in France, following earlier acquisitions in the United Kingdom, Germany, Ireland, and India.
- 1999
Wockhardt Ltd. incorporated
[1]Wockhardt Ltd. was incorporated on 8 July 1999.
- 1995
Entry into biotechnology
[1]Wockhardt expanded beyond conventional pharmaceutical formulations into biotechnology.
- 1973
Wockhardt Pvt. Ltd. incorporated
[1]The Wockhardt private company was incorporated.
- 1960
Wockhardt origins
[1]The company’s origins are dated to the 1960s under Dr. Habil Khorakiwala.
Products and positioning
An internationally oriented Indian pharmaceutical and biotechnology company focused on branded generics, biopharmaceuticals, vaccines, APIs, and regulated-market manufacturing.
Pain medicine
Proxyvon
Proxyvon was one of the products associated with Wockhardt’s expansion in the Indian pharmaceutical market during the 1990s. Reference material identifies it as a painkiller combining tramadol and paracetamol. Its historical importance lies in its contribution to the company’s branded-formulations business, rather than in evidence that it remains a current flagship product.
Branded generics
Cardiovascular medicines
Wockhardt built market share in the 1990s with blood-pressure medicines, including products based on lisinopril. These medicines represent the company’s conventional branded-generic and cardiovascular portfolio, although the reference material does not provide a complete current product list.
Biopharmaceutical
Recombinant human insulin
Wockhardt developed manufacturing capability for recombinant human insulin and is described in the reference material as the first company outside the United States and Europe to manufacture it. The product illustrates the company’s move into biotechnology and biologic medicines.
Vaccine manufacturing service · 2020
Oxford–AstraZeneca COVID-19 vaccine fill-finish
Wockhardt’s facility in Wrexham, Wales provided fill-finish manufacturing for the Oxford–AstraZeneca COVID-19 vaccine under an agreement with the Government of the United Kingdom. The arrangement was extended through August 2022.
Vaccine contract manufacturing · 2021
Sputnik V and Sputnik Light
In 2021, Wockhardt announced an agreement involving Enso Healthcare and Human Vaccine LLC to contract manufacture Sputnik V and Sputnik Light vaccines in India. The available reference does not establish the eventual commercial scale or duration of production.
Pharmaceutical raw materials
Active pharmaceutical ingredients
APIs are part of Wockhardt’s stated business scope. They support the company’s formulation, generic-drug, and manufacturing activities, but the supplied material does not identify individual API molecules or current sales lines.
Controversies
2013
Good manufacturing practice and data-integrity controversy
The U.S. Food and Drug Administration reported serious problems at Wockhardt’s Aurangabad manufacturing facility, including alleged widespread fraud, data-integrity failures, contamination concerns involving injectable medicines, and other good-manufacturing-practice violations. The agency restricted the facility’s ability to export medicines. The reference material also states that Wockhardt officials repeatedly threatened FDA inspectors.
Cultural association with codeine cough syrup
The Wockhardt name has been used in popular-culture slang because a codeine- and promethazine-containing cough syrup associated with the brand is referenced in discussions of recreational 'lean'. The available material does not identify this as a corporate misconduct finding or a regulatory case against the brand.
Brand decisions
2021
Sputnik vaccine contract manufacturing agreementProduct launchBackground
Wockhardt pursued additional vaccine manufacturing opportunities during the global COVID-19 response.
Action taken
The company announced an agreement with Enso Healthcare and Human Vaccine LLC to manufacture Sputnik V and Sputnik Light vaccines in India.
Aftermath
The available reference confirms the announcement but does not establish the final production volume, regulatory outcome, or commercial duration.
2020
COVID-19 vaccine fill-finish partnershipProduct launchBackground
The COVID-19 pandemic created demand for additional vaccine manufacturing and packaging capacity in the United Kingdom.
Action taken
Wockhardt agreed to fill and finish the Oxford–AstraZeneca COVID-19 vaccine at its Wrexham facility for the UK government.
Aftermath
The agreement was extended through August 2022 and gave Wockhardt a role in a high-profile vaccine supply chain.
2011
Sale of nutrition business to DanoneM&ABackground
Following acquisition-driven expansion and increased debt, Wockhardt reshaped its portfolio.
Action taken
Wockhardt sold its nutrition business to Danone.
Aftermath
The transaction removed the nutrition business from Wockhardt’s portfolio and concentrated the group more heavily on pharmaceuticals, biotechnology, and related manufacturing.
Reported transaction value. $356 million (2011)
2007
Acquisition-led international expansionM&ABackground
Wockhardt sought international market access, manufacturing assets, and pharmaceutical portfolios through acquisitions.
Action taken
The company acquired Morton Grove Pharmaceuticals in the United States and Negma in France, after earlier purchases in the United Kingdom, Germany, Ireland, and India.
Aftermath
The acquisition program expanded the group’s international footprint but contributed to debt that the reference material places near Rs 38 billion, followed by a management transition.
Debt following acquisitions. Close to Rs 38 billion (After the acquisition program, before the 2009 management transition)
1995
Expansion into biotechnologyStrategyBackground
Wockhardt was developing beyond conventional pharmaceutical formulations and seeking capabilities in higher-value biological medicines.
Action taken
The company entered biotechnology and later developed recombinant human insulin manufacturing capability.
Aftermath
The move broadened Wockhardt’s identity from a formulations company toward a pharmaceutical and biotechnology group.
Recent events
Wockhardt reports Q1 FY27 profit[3]
Wockhardt reported consolidated net profit of Rs 107 crore for Q1 FY27, compared with a loss of Rs 108 crore a year earlier.
- Unconfirmed
Wockhardt launches Antibiotic Academy[3]
Wockhardt announced the launch of the Wockhardt Antibiotic Academy, an open scientific learning platform for doctors focused on evidence-based dialogue on antimicrobial resistance and appropriate antibiotic use.
- Unconfirmed
Wockhardt partners with RDIF to produce and supply Sputnik vaccines[4]
Reported:
Wockhardt partnered with the Russian Direct Investment Fund to produce and supply Sputnik V and Sputnik Light COVID-19 vaccines. The agreement was reached under the aegis of Enso Healthcare, RDIF’s coordination partner for sourcing Sputnik V vaccines in India.
Wockhardt and RDIF vaccine production and supply partnership[5]
Reported:
Wockhardt and the Russian Direct Investment Fund (RDIF) partnered to produce and supply Sputnik V and Sputnik Light COVID-19 vaccines. The agreement was reached under the aegis of Enso Healthcare, RDIF's coordination partner for sourcing Sputnik V vaccines in India.
Wockhardt appoints Akhilesh Gupta as additional director[6]
Reported:
Wockhardt appointed Akhilesh Gupta as an additional director, serving as a non-executive, independent director, effective August 29, 2020.
Wockhardt announces UK COVID-19 vaccine manufacturing agreement[7]
Reported:
Wockhardt announced an agreement with the UK Government to fill and finish COVID-19 vaccines. Manufacturing is to take place at CP Pharmaceuticals, a Wockhardt subsidiary in Wrexham, and the agreement reserves manufacturing capacity for multiple vaccine candidates.
Dr. Reddy’s completes acquisition of selected Wockhardt business divisions[8]
Reported:
Dr. Reddy’s Laboratories completed its acquisition of selected divisions of Wockhardt’s branded generics business in India and several other territories. The transferred business included 62 brands, related sales and marketing teams, and a manufacturing plant.
Sources13 sources
- 1Wockhardten.wikipedia.org
- 2Wockhardt official websitewockhardt.com
- 3Wockhardt公布2027财年第一季度盈利moneycontrol.com
- 4Wockhardt 与 RDIF 合作生产并供应 Sputnik 疫苗businesstoday.in
- 5Wockhardt 与 RDIF 疫苗生产及供应合作business-standard.com
- 6Wockhardt任命Akhilesh Gupta为额外董事financialexpress.com
- 7Wockhardt宣布与英国政府达成新冠疫苗制造协议equitybulls.com
- 8瑞迪博士完成收购沃克哈特部分业务部门business-standard.com
- 9Dr Reddy-'s acquires select business divisions of Wockhardt | Dr Reddy\'s acquires select business divisions of Wockhardtdeccanchronicle.com
- 10Dr Reddy's completes acquisition of Wockhardt's select business divisionsaninews.in
- 11Dr Reddyâs completes acquisition of Wockhardtâs branded generics businessthehindubusinessline.com
- 12Dr. Reddy's Laboratories completes the acquisition of select business divisions of Wockhardtequitybulls.com
- 13DRL acquires Wockhardt divisions with amended pactthehindu.com
Cite this profile: Cite the canonical profile. /brand-wiki/wockhardt · Editorial policy · How profiles are compiled